155 related articles for article (PubMed ID: 12445424)
1. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.
Suzuki F; Suzuki Y; Tsubota A; Akuta N; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Hepatol; 2002 Dec; 37(6):824-30. PubMed ID: 12445424
[TBL] [Abstract][Full Text] [Related]
2. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
Cho SW; Hahm KB; Kim JH
Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
[TBL] [Abstract][Full Text] [Related]
3. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
[TBL] [Abstract][Full Text] [Related]
4. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
[TBL] [Abstract][Full Text] [Related]
5. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
6. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
7. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
8. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
9. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
10. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
[TBL] [Abstract][Full Text] [Related]
11. [The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].
Kim HJ; Yoo BC
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):149-56. PubMed ID: 12499800
[TBL] [Abstract][Full Text] [Related]
12. HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
J Med Virol; 2003 Jul; 70(3):355-60. PubMed ID: 12766997
[TBL] [Abstract][Full Text] [Related]
13. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
14. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea.
Yoo BC; Park JW; Kim HJ; Lee DH; Cha YJ; Park SM
J Hepatol; 2003 Jan; 38(1):98-103. PubMed ID: 12480566
[TBL] [Abstract][Full Text] [Related]
15. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.
Buti M; Jardi R; Rodriguez-Frias F; Valdes A; Schaper M; Esteban R; Guardia J
Aliment Pharmacol Ther; 2005 Jun; 21(11):1349-56. PubMed ID: 15932365
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays.
Zampino R; Marrone A; Finnström N; Eriksson T; Törmänen V; Hedrum A; Attanasio V; Rosario P; Utili R; Ruggiero G
Infez Med; 2005 Jun; 13(2):86-96. PubMed ID: 16220028
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels.
Bozdayi AM; Bozkaya H; Türkyilmaz AR; Sarýodlu M; Cetinkaya H; Karayalçin S; Yurdaydin C; Uzunalimoğlu O
J Clin Virol; 2001 Apr; 21(1):91-101. PubMed ID: 11255102
[TBL] [Abstract][Full Text] [Related]
19. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
[TBL] [Abstract][Full Text] [Related]
20. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
